Amicus Therapeutics, Inc. FOLD
14.49 USD 0.00 (+0.00%)
At closeApr 27, 2026, 4:00 PM EDT
14.49 0.00 0.00%
After hours · Apr 27, 4:00 PM ET
14.49 Day range 14.49
52-week range unavailable
- YTD
- +1.76%
- 1 year
- +97.14%
News
nypost.com Bitcoin surges above $70K as Trump backs Clarity Act, Treasury ramps up buybacks Bitcoin jumped 4.6% to $72,475.25 – a roughly 12% gain over the past two days after the digital asset was trading near $63,000 earlier this week.
benzinga.com This Hedge Fund Portfolio Shrinks 17% as Billionaire Bets Big on Gold Paulson's hedge fund reduced its equity book to $2.58B in Q2, exiting two positions and opening a stake in Alphabet.
seekingalpha.com BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition BioMarin Pharmaceutical remains a "Strong Buy," driven by pipeline progress, strategic acquisitions, and robust revenue guidance. BMRN's acquisition of Amicus Therapeutics adds GALAFOLD and POMBILITI…
fool.com CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD) Amicus Therapeutics targets rare genetic diseases with proprietary therapies and a pipeline of treatments for underserved patient groups.
seekingalpha.com BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A Buy BioMarin (BMRN) has declined over 12% since January 2025, despite prior optimism. The investment thesis centers on the potential of VOXZOGO and Amicus's two approved therapies to drive future upside.…
defenseworld.net SG Americas Securities LLC Acquires 36,938 Shares of Amicus Therapeutics, Inc. $FOLD SG Americas Securities LLC boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ: FOLD) by 53.2% during the undefined quarter, according to the company in its most recent 13F filing with the…
defenseworld.net Capricorn Fund Managers Ltd Invests $3 Million in Amicus Therapeutics, Inc. $FOLD Capricorn Fund Managers Ltd bought a new stake in Amicus Therapeutics, Inc. (NASDAQ: FOLD) during the undefined quarter, according to the company in its most recent disclosure with the Securities and…
businesswire.com Leading Financial Trade Associations, Led by LSTA, Submit Amicus Brief in Support of Defendant Lenders in Antitrust Case Filed by Optumum Communications NEW YORK--(BUSINESS WIRE)--LSTA, the trade association for the U.S. corporate lending market, today was joined by SIFMA, the MFA, the Investment Company Institute and the Creditor Rights Coalition,…
defenseworld.net Avoro Capital Advisors LLC Decreases Stock Holdings in Amicus Therapeutics, Inc. $FOLD Avoro Capital Advisors LLC reduced its stake in Amicus Therapeutics, Inc. (NASDAQ: FOLD) by 16.5% in the undefined quarter, according to the company in its most recent 13F filing with the Securities…
reuters.com Microsoft files amicus brief in support of Anthropic's lawsuit with US DOD Microsoft filed on Tuesday a proposed brief in support of Anthropic's lawsuit asking the court to temporarily block the U.S. Department of Defense's designation of the AI startup as a…
zacks.com Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues FOLD's Q4 earnings miss, but revenues beat estimates on strong Galafold and Pombiliti sales. The company is set to be acquired by BioMarin for $4.8 billion.
defenseworld.net Amicus Therapeutics, Inc. $FOLD Shares Sold by Granite Investment Partners LLC Granite Investment Partners LLC cut its stake in Amicus Therapeutics, Inc. (NASDAQ: FOLD) by 2.0% in the undefined quarter, according to its most recent Form 13F filing with the Securities and…
globenewswire.com Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates 2025 Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position of $294M, a $44M Increase in 2025 Proposed Acquisition by BioMarin Expected to Close in Q2 2026, Subject to Closing Conditions…
zacks.com What to Expect From These Drug/Biotech Players This Earnings Season? Let's take a closer look at what awaits Bausch Health, Amicus Therapeutics, BioMarin Pharmaceutical, Insmed and Madrigal Pharmaceuticals as they prepare to report quarterly results this week.
zacks.com Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? FOLD heads into Q4 earnings with Galafold driving growth and Pombiliti + Opfolda aiding the top line. BioMarin is set to acquire the company for $4.8 billion.
globenewswire.com Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026 PRINCETON, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new data from clinical and real-world studies of Galafold® (migalastat) in…
benzinga.com Top 3 Health Care Stocks That May Implode In Q1 
zacks.com FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside? Amicus and Rigel target rare diseases, but a pending BioMarin buyout and growing drug sales set up different upside paths for investors.
defenseworld.net Bradley Campbell Sells 75,000 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock Amicus Therapeutics, Inc. (NASDAQ: FOLD - Get Free Report) CEO Bradley Campbell sold 75,000 shares of the company's stock in a transaction dated Tuesday, January 20th. The shares were sold at an…
businesswire.com FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Amicus Therapeutics, Inc. (NASDAQ: FOLD) to BioMarin Pharmaceutical Inc. for $14.50 per…
247wallst.com Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Callaway Golf, Datadog, Hyatt Hotels, Palantir, Texas Instruments, Verizon, and More Pre-Market Stock Futures: The futures are trading higher this morning, following a solid bounce-back rally across the major indices on Wednesday, after the worst day for stocks since October. Stocks…
benzinga.com Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday 
benzinga.com Nasdaq Surges Over 1%; Lamb Weston Shares Decline Following Q2 Results 
benzinga.com Carnival Posts Strong Q4 Earnings, Joins Amicus Therapeutics, Biomarin Pharmaceutical And Other Big Stocks Moving Higher On Friday 
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com Earnings Scheduled For November 4, 2025 
benzinga.com Earnings Scheduled For July 31, 2025 
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Earnings Scheduled For May 1, 2025 
benzinga.com Earnings Scheduled For February 19, 2025 
benzinga.com Travelers Posts Upbeat Results, Joins Iridium Communications, Snap-on And Other Big Stocks Moving Higher On Thursday 
benzinga.com Earnings Scheduled For February 28, 2024 Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion.- benzinga.com Earnings Scheduled For November 8, 2023 Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.
- benzinga.com Earnings Scheduled For August 8, 2023 Companies Reporting Before The Bell • Warner Music Gr (NASDAQ:WMG) is likely to report quarterly earnings at $0.21 per share on revenue of $1.48 billion.
- benzinga.com Earnings Scheduled For May 10, 2023 Companies Reporting Before The Bell • Nomad Foods (NYSE:NOMD) is projected to report quarterly earnings at $0.42 per share on revenue of $851.81 million.
benzinga.com Earnings Scheduled For March 1, 2023 Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.- benzinga.com Earnings Scheduled For November 7, 2022 Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million.
- benzinga.com Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know Editor's note: This story has been corrected to reflect that the FDA deferred action on Amicus Therapeutics' Biologics License Application.
- benzinga.com Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday Gainers
- benzinga.com Earnings Scheduled For August 4, 2022 Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
- benzinga.com Earnings Scheduled For May 9, 2022 Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 1043 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's trading, 435 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday, 849 stocks hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 784 companies set new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For January 14, 2022 Upgrades- benzinga.com 45 Stocks Moving In Monday's Mid-Day Session Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares climbed 71.5% to $5.88.
- benzinga.com The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data Here's a roundup of top developments in the biotech space over the last 24 hours:
- benzinga.com Earnings Scheduled For November 9, 2021 Companies Reporting Before The Bell • Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter. • KT (NYSE:KT) is projected to report earnings for its third quarter.